Physician profile
Devin M West
NPI 1952707747
$6,984.05
in general payments reported to CMS, 2019-2025
22 companies · $2,705 in 2025
The $2,705 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $638 · 2021: $185 · 2022: $402 · 2023: $616 · 2024: $2,158 · 2025: $2,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,774 · Travel and Lodging: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,773.57 |
| Travel and Lodging | $705.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,925.06 | 2019-2025 | Unity, Clareon, Ngenuity |
| Biotissue Holdings INC. | $1,573.21 | 2023-2025 | |
| Abbvie INC. | $637.22 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Ocular Therapeutix, INC. | $563.54 | 2023-2025 | Dextenza |
| Ivantis, INC | $500.00 | 2020 | |
| Rayner Intraocular Lenses Limited | $399.36 | 2022-2025 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Sight Sciences, INC. | $316.46 | 2022-2025 | Omni Surgical System, Tearcare System |
| Rxsight INC | $176.59 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Aerie Pharmaceuticals, INC. | $166.18 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $125.00 | 2025 | Syfovre |
| Dompe US, INC. | $93.84 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $93.74 | 2022-2025 | Vyzulta, Miebo, Prolensa |
| Johnson & Johnson Surgical Vision, INC. | $70.56 | 2022-2024 | Veritas Vision System, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.93 | 2021 | |
| Glaukos Corporation | $46.87 | 2019-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $43.85 | 2023-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $42.19 | 2020-2023 | |
| Omeros Corporation | $40.11 | 2019-2021 | |
| Oyster Point Pharma, INC. | $39.72 | 2023-2024 | Tyrvaya, Ryzumvi |
| Amgen INC. | $39.19 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $28.03 | 2023 | Tepezza |
| New World Medical,INC. | $15.40 | 2021-2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.